NYSE:NUVBPharmaceuticals
Nuvation Bio (NUVB) Q4 Revenue Surge Tests Bullish Growth Narrative Against Ongoing Losses
Nuvation Bio FY 2025 Earnings Snapshot
Nuvation Bio (NUVB) has wrapped up FY 2025 with fourth quarter revenue of about US$41.9 million and a basic EPS loss of US$0.11, as the market weighs solid top line figures against continued bottom line pressure. The company has seen revenue move from US$5.7 million in Q4 2024 to US$41.9 million in Q4 2025, while quarterly basic EPS has ranged from a loss of US$0.15 in Q4 2024 to a loss of US$0.11 in Q4 2025 and a trailing twelve month basic EPS loss of...